#United States #Class Action #Los Angeles #Takeda #Actos

Class Action Lawsuit Against Takeda: A Deep Dive

In what could be a landmark case, a class action lawsuit has been certified against Takeda Pharmaceuticals USA, Inc. and its parent company, Takeda Pharmaceutical Company Limited, along with Eli Lilly Company, regarding their diabetes drug, Actos and its related products. This lawsuit, which has the potential to affect third-party payors (TPPs) across the United States, stems from claims that the manufacturers concealed serious health risks associated with the drug, specifically the link to bladder cancer.

Background of the Lawsuit

The class action was initiated to address allegations that the defendants violated the Racketeer Influenced and Corrupt Organizations Act (RICO). The primary claim suggests that TPPs who reimbursed prescriptions for Actos, ActosPlus MET, ActosPlus MET XR, Duetact, and Oseni did so under false pretenses, as they were not informed of the full risks involved with the medication. This situation apparently resulted in TPPs approving reimbursement for a significant number of claims that they might otherwise have denied had they been aware of the risks.

Who is Affected?

The class action impacts TPPs in the United States that bought or reimbursed costs for the aforementioned medications within a specific timeframe: from July 1, 1999, to September 17, 2010. To be included in the class, these TPPs must have processed five or more independent prescriptions for the drugs in question, aimed solely for patient use and not for resale. It's important to note that TPPs that have previously settled or released claims related to this lawsuit are excluded from participation.

What Are the Options for TPPs?

As a TPP, if you find yourself part of this class, you will need to decide whether to remain in the lawsuit or to opt out. Staying in the class means that if there are any financial benefits or remedies awarded as a result of the lawsuit, you will be notified on how to proceed in obtaining your share. However, remaining in the class binds you to accept the court's decisions, whether favorable or adverse, and limits your ability to bring separate lawsuits regarding these claims.

If you wish to exclude yourself from the class action, it's imperative to take action by sending a letter requesting exclusion. Instructions for this process are accessible online at www.ActosClassAction.com or by contacting the specified toll-free number. Exclusion requests must be postmarked by April 6, 2026. However, opting out means you forfeit any potential benefits from the lawsuit.

Legal Representation

For those who choose to remain part of the class, legal representation would be provided by the law firms of Wisner Baum, LLP and Pendley, Baudin Coffin, LLP, at no upfront cost to the class members. There is an option to hire an independent attorney, but any fees incurred would be the responsibility of the TPP.

Next Steps

For TPPs that believe they are entitled to benefits, the situation requires careful navigation. Detailed information concerning rights related to the lawsuit can be found by calling the designated phone number or visiting the online platform. If successful, this class action could pave the way for significant repercussions not only for Takeda and Eli Lilly but also for the pharmaceutical industry at large. As the case unfolds, it will be critical for affected parties to keep abreast of developments and understand their position within this ongoing litigation.

As a final thought, this lawsuit underscores the importance of transparency in pharmaceutical practices and serves as a reminder of the potential consequences of undisclosed risks linked to medication. Stakeholders are advised to act promptly to ensure their interests are adequately represented as this case progresses.